Tscan Therapeutics Q4 2021 Earnings Report
Key Takeaways
TScan Therapeutics reported its full year 2021 financial results, highlighting FDA clearance of IND for TSC-100, the upcoming initiation of a Phase 1 trial for the liquid tumor program, and a strong balance sheet with $161.4 million in cash and cash equivalents.
Received FDA clearance of IND for TSC-100 for hematologic malignancies treatment.
Phase 1 umbrella trial for liquid tumor program is expected to start in H1 2022, with preliminary data anticipated in H2 2022.
Two INDs for the TSC-200 series are expected by the end of the year.
The company reported a strong financial position, with $161.4 million in cash and cash equivalents as of December 31, 2021, which is expected to fund operations into 2024.
Tscan Therapeutics
Tscan Therapeutics
Tscan Therapeutics Revenue by Segment
Forward Guidance
TScan Therapeutics is focused on advancing its liquid and solid tumor programs, with key milestones expected in 2022, including initiating a Phase 1 trial for TSC-100, presenting preclinical data on the TSC-200 series, and submitting two IND applications.
Positive Outlook
- Initiate Phase 1 umbrella trial for TSC-100 in H1 2022.
- Present initial clinical data from the liquid tumor program in H2 2022.
- Present initial preclinical data on the TSC-200 series in H1 2022.
- Submit two IND applications for the TSC-200 series in H2 2022.
- Continue research into potential T cell focused COVID-19 vaccine constructs.
Challenges Ahead
- FDA placed a clinical hold on the IND for TSC-101 in January 2022.
- The company is working with the FDA to resolve questions regarding potential off-tumor reactivity of TSC-101.
- Resolution of the clinical hold on TSC-101 is necessary to open the TSC-101 arm of the ongoing trial.
- Success of clinical trials and preclinical studies is subject to risks and uncertainties.
- The COVID-19 pandemic could affect TScan's business and operations.